Total Payments
$417,633
2024 Payments
$38,645
Companies
13
Transactions
389
Medicare Patients
1,229
Medicare Billing
$207,341
Payment Breakdown by Category
Consulting$209,591 (50.2%)
Research$98,656 (23.6%)
Travel$54,193 (13.0%)
Other$46,978 (11.2%)
Food & Beverage$7,266 (1.7%)
Royalty/License$930.00 (0.2%)
Education$19.99 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $209,591 | 62 | 50.2% |
| Unspecified | $98,656 | 18 | 23.6% |
| Travel and Lodging | $54,193 | 134 | 13.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $28,603 | 8 | 6.8% |
| Honoraria | $18,375 | 7 | 4.4% |
| Food and Beverage | $7,266 | 156 | 1.7% |
| Royalty or License | $930.00 | 3 | 0.2% |
| Education | $19.99 | 1 | 0.0% |
Payments by Type
General
$318,977
371 transactions
Research
$98,656
18 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ViiV Healthcare Company | $111,029 | 115 | $0 (2024) |
| Eli Lilly and Company | $89,374 | 1 | $0 (2020) |
| Merck Sharp & Dohme LLC | $85,461 | 93 | $0 (2024) |
| Gilead Sciences, Inc. | $47,498 | 70 | $0 (2024) |
| Theratechnologies Inc. | $32,037 | 45 | $0 (2023) |
| Janssen Scientific Affairs, LLC | $14,117 | 40 | $0 (2021) |
| Amgen Inc. | $12,525 | 3 | $0 (2021) |
| Shionogi Inc | $9,336 | 10 | $0 (2019) |
| Bayer HealthCare Pharmaceuticals Inc. | $9,042 | 1 | $0 (2017) |
| Janssen Products, LP | $3,075 | 5 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $38,645 | 29 | ViiV Healthcare Company ($21,850) |
| 2023 | $63,385 | 73 | Merck Sharp & Dohme LLC ($41,544) |
| 2022 | $32,295 | 25 | ViiV Healthcare Company ($16,848) |
| 2021 | $18,554 | 12 | Amgen Inc. ($5,531) |
| 2020 | $111,186 | 18 | Eli Lilly and Company ($89,374) |
| 2019 | $73,954 | 104 | Merck Sharp & Dohme Corporation ($23,078) |
| 2018 | $34,063 | 62 | ViiV Healthcare Company ($22,726) |
| 2017 | $45,552 | 66 | Gilead Sciences Inc ($16,238) |
All Payment Transactions
389 individual payment records from CMS Open Payments — Page 1 of 16
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $4,650.00 | General |
| 12/11/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| 12/03/2024 | Merck Sharp & Dohme LLC | DELSTRIGO (Drug) | Food and Beverage | In-kind items and services | $64.99 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 12/03/2024 | Merck Sharp & Dohme LLC | DELSTRIGO (Drug) | Food and Beverage | In-kind items and services | $59.97 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 12/03/2024 | Merck Sharp & Dohme LLC | DELSTRIGO (Drug) | Food and Beverage | In-kind items and services | $55.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 12/02/2024 | Merck Sharp & Dohme LLC | DELSTRIGO (Drug) | Travel and Lodging | In-kind items and services | $260.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 12/02/2024 | Merck Sharp & Dohme LLC | DELSTRIGO (Drug) | Travel and Lodging | In-kind items and services | $219.94 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 12/02/2024 | Merck Sharp & Dohme LLC | DELSTRIGO (Drug) | Travel and Lodging | In-kind items and services | $197.40 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 12/02/2024 | Merck Sharp & Dohme LLC | DELSTRIGO (Drug) | Travel and Lodging | In-kind items and services | $142.50 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/14/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $35.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/15/2024 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,800.00 | General |
| 08/14/2024 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $123.46 | General |
| 06/19/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 06/04/2024 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,150.00 | General |
| 05/29/2024 | ViiV Healthcare Company | DOVATO (Drug) | Consulting Fee | Cash or cash equivalent | $650.00 | General |
| Category: HIV | ||||||
| 05/06/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $1,860.00 | General |
| 05/02/2024 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,150.00 | General |
| 04/26/2024 | ViiV Healthcare Company | DOVATO (Drug) | Travel and Lodging | Cash or cash equivalent | $147.74 | General |
| Category: HIV | ||||||
| 04/26/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | Cash or cash equivalent | $60.25 | General |
| Category: HIV | ||||||
| 04/24/2024 | ViiV Healthcare Company | DOVATO (Drug) | Consulting Fee | Cash or cash equivalent | $3,900.00 | General |
| Category: HIV | ||||||
| 03/07/2024 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $95.70 | General |
| 03/07/2024 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $80.66 | General |
| 03/07/2024 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $32.81 | General |
| 03/07/2024 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $26.13 | General |
| 03/07/2024 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $6.84 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS | Eli Lilly and Company | $89,374 | 1 |
| Ph3b Evolocumab in HIV Patients | Amgen Inc. | $6,994 | 1 |
| A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV | Gilead Sciences, Inc. | $1,435 | 15 |
| SAFETY AND EFFICACY OF TOCILIZUMAB 4 MGKG OR 8 MGKG IN HOSPITALIZED PATIENTS WITH MODERATE-TO-SEVERE COVID-19 PNEUMONIA A RANDOMIZED CLINICAL TRIAL | F. Hoffmann-La Roche AG | $852.94 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 195 | 338 | $100,194 | $36,275 |
| 2022 | 12 | 506 | 719 | $202,809 | $90,214 |
| 2021 | 4 | 174 | 348 | $75,229 | $29,406 |
| 2020 | 5 | 354 | 697 | $142,928 | $51,446 |
Total Patients
1,229
Total Services
2,102
Medicare Billing
$207,341
Procedure Codes
26
All Medicare Procedures & Services
26 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 43 | 106 | $28,905 | $11,232 | 38.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 47 | 67 | $25,876 | $9,421 | 36.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 41 | 95 | $17,605 | $6,667 | 37.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 35 | 38 | $18,461 | $5,713 | 30.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 29 | 32 | $9,347 | $3,242 | 34.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 142 | 189 | $66,717 | $29,014 | 43.5% |
| M0220 | Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise | Office | 2022 | 104 | 135 | $33,426 | $22,994 | 68.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 45 | 121 | $30,250 | $11,079 | 36.6% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 50 | 101 | $17,473 | $6,423 | 36.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 46 | 54 | $14,362 | $5,640 | 39.3% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 29 | 29 | $7,714 | $2,911 | 37.7% |
| 99496 | Transitional care management services for problem of high complexity | Office | 2022 | 11 | 11 | $7,227 | $2,859 | 39.6% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 16 | 16 | $7,776 | $2,829 | 36.4% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 18 | 18 | $5,904 | $2,177 | 36.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 13 | 13 | $5,213 | $1,831 | 35.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 21 | 21 | $3,860 | $1,428 | 37.0% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 11 | 11 | $2,887 | $1,029 | 35.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 80 | 229 | $39,617 | $14,849 | 37.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 38 | 58 | $15,254 | $6,501 | 42.6% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 44 | 47 | $15,416 | $5,793 | 37.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 12 | 14 | $4,942 | $2,264 | 45.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 170 | 492 | $85,116 | $31,564 | 37.1% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 125 | 128 | $42,124 | $14,575 | 34.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 29 | 37 | $9,731 | $3,102 | 31.9% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 12 | 13 | $3,419 | $1,248 | 36.5% |
About Princy Kumar
Princy Kumar is a Infectious Disease healthcare provider based in Washington, District of Columbia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/20/2005. The National Provider Identifier (NPI) number assigned to this provider is 1790784957.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Princy Kumar has received a total of $417,633 in payments from pharmaceutical and medical device companies, with $38,645 received in 2024. These payments were reported across 389 transactions from 13 companies. The most common payment nature is "Consulting Fee" ($209,591).
As a Medicare-enrolled provider, Kumar has provided services to 1,229 Medicare beneficiaries, totaling 2,102 services with total Medicare billing of $207,341. Data is available for 4 years (2020–2023), covering 26 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Washington, DC
- Active Since 07/20/2005
- Last Updated 03/08/2012
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1790784957
Products in Payments
- TROGARZO (Drug) $17,368
- DOVATO (Drug) $15,117
- Repatha (Biological) $12,525
- Descovy (Drug) $9,768
- Fetroja (Drug) $9,336
- Cipro (Drug) $9,042
- MK-8591A (Drug) $8,891
- EDURANT (Drug) $8,611
- TIVICAY (Drug) $5,010
- PREZISTA (Drug) $4,576
- SYMTUZA (Drug) $3,010
- VOWST (Biological) $3,000
- MK-8591 (Drug) $1,955
- DELSTRIGO (Drug) $999.80
- Actemra (Biological) $852.94
- EGRIFTA (Drug) $138.83
- Truvada (Drug) $103.76
- PREZCOBIX (Drug) $65.43
- TRIUMEQ (Drug) $62.90
- APRETUDE (Biological) $12.31
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Washington
Dr. Robert Gasser, Md, MD
Infectious Disease — Payments: $922,181
Infectious Disease $922,181
Dr. Jose Chavez, Md, MD
Infectious Disease — Payments: $293,279
Infectious Disease $293,279
Dr. Gebeyehu Teferi, M.d, M.D
Infectious Disease — Payments: $97,206
Infectious Disease $97,206
Dawn Fishbein, Md, MD
Infectious Disease — Payments: $24,671
Infectious Disease $24,671
Dr. Glenn Wortmann, M.d, M.D
Infectious Disease — Payments: $14,236
Infectious Disease $14,236
Rebecca Kumar, M.d, M.D
Infectious Disease — Payments: $12,926
Infectious Disease $12,926